Warren Rose, associate professor (CHS) in the Pharmacy Practice Division is the principal investigator of new research grant funded by Theravance BioPharma that will study a new clinical antibiotic Telavancin and its mechanical properties and antibiotic activity in bone cement. This study will determine the potential for Telavancin use in bone cements to prevent surgical site infections in patients and compare it to the common standard Vancomycin. The project is a collaboration between investigators at the School of Pharmacy (Rose), Department of Mechanical Engineering (Heidi-Lynn Ploeg, PhD), and Department of Orthopedics and Rehabilitation (Matthew Squire, MD, MS) at UW-Madison.

Rose’s research interests include antimicrobial resistance and pharmacodynamics and antimicrobial effects on host-pathogen interactions.